Document Detail

Long-term use of valproate in primary psychiatric disorders.
MedLine Citation:
PMID:  2494158     Owner:  NLM     Status:  MEDLINE    
Thirty-five patients, all with major depressive illness, bipolar disorder, or schizoaffective disorder, were retrospectively identified as having received valproate either alone or in combination with lithium, after having failed to adequately respond to previous lithium and/or carbamazepine treatment. Clinical evaluation and Global Assessment Scale (GAS) scores indicated that at baseline all but 3 of the patients experienced serious psychiatric symptoms, serious impairment in social or professional functioning, or significant impairment in reality testing. Mean GAS scores after a mean duration of at least 1 year of valproate administration improved in 7 of 9 depressed patients, 12 of 12 patients with bipolar disorder, and 11 of 14 patients with schizoaffective states. Mean increases in GAS scores were 27.7 points for depressive disorder patients, 34.5 points for mixed bipolar disorder patients, and 17.1 points for patients with schizoaffective states. For patients with either depressive disorders or mixed bipolar disorders, that mean change represented a level of improvement sufficient to elevate the majority of the patients into the mild symptom range or the virtually asymptomatic state. That improvement was confirmed by the investigator's global evaluation of patient response with regard to affect: valproate administration produced significant affective responses in 7 of 9 depressed patients, 12 of 12 patients with mixed bipolar disorders, and 11 of 14 patients with schizoaffective states. The responses of patients with bipolar and schizoaffective disorders to valproate treatment compared with valproate plus lithium treatment were also evaluated. Patients in both diagnostic categories demonstrated very similar and quite substantial improvement in mean change in GAS ratings and global evaluations, regardless of whether valproate was administered alone or in combination with lithium.
S G Hayes
Related Documents :
9792378 - Effect of indinavir on hiv-related wasting.
10695418 - Assessment of malnutrition in alcoholic and non alcoholic cirrhotics.
10836368 - Relation between steroid dose, body composition and physical activity in renal transpla...
4045748 - Anorexia nervosa in the male: clinical features and follow-up of nine patients.
13679808 - Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid gene...
7279818 - Prevalence of thyroid antibodies in shiraz, iran, an area with iodine deficiency.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  50 Suppl     ISSN:  0160-6689     ISO Abbreviation:  J Clin Psychiatry     Publication Date:  1989 Mar 
Date Detail:
Created Date:  1989-04-24     Completed Date:  1989-04-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  35-9     Citation Subset:  IM    
Department of Psychiatry, University of Southern California School of Medicine.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bipolar Disorder / drug therapy,  psychology
Clinical Trials as Topic
Depressive Disorder / drug therapy*,  psychology
Drug Therapy, Combination
Follow-Up Studies
Lithium / therapeutic use
Psychiatric Status Rating Scales
Psychotic Disorders / drug therapy*,  psychology
Valproic Acid / therapeutic use*
Reg. No./Substance:
7439-93-2/Lithium; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phenomenology of rapid cycling manic depression and its treatment with valproate.
Next Document:  The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar...